<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832284</url>
  </required_header>
  <id_info>
    <org_study_id>E7113</org_study_id>
    <nct_id>NCT02832284</nct_id>
  </id_info>
  <brief_title>iNod System Human Feasibility Assessment</brief_title>
  <acronym>iNod</acronym>
  <official_title>Feasibility Study of a Bronchoscopic Ultrasound-Guided Tissue Acquisition System With Real-time Visualization for Collection of Cytology Specimens of Peripheral Pulmonary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate feasibility to access, visualize, and obtain
      specimens adequate for cytology of lung lesions in subjects with suspected lung cancer when
      using the iNod System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a traditional feasibility study for the sampling of a peripheral pulmonary
      lesion in the setting of a suspicion of lung cancer. Standard of practice radial
      endobronchial ultrasound (R-EBUS) transbronchial needle aspiration (TBNA) is visualizing a
      peripheral lesion on R-EBUS, locking the placement of the access sheath, removing the
      ultrasound catheter from the access sheath and then blindly advancing a sampling device to
      acquire cellular matter for cytologic evaluation. The iNod system performs the same procedure
      with one fewer device exchange. It provides real-time visualization of the biopsy needle and
      target peripheral pulmonary lesions during tissue acquisition. The ultrasound probe is not
      retracted in advance of the sampling maneuver and the sampling is completed under direct
      visualization. Compared to current standard of care methods for transbronchial sampling of
      pulmonary lesions, this approach is not expected to add additional risk. Tissue sampling
      under real-time visualization may improve the efficiency of tissue sampling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2017</start_date>
  <completion_date type="Actual">June 14, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acquisition of Adequate Specimens of Targeted Lung Lesions</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>The primary endpoint for the iNod Feasibility Study was clinical success, defined as the iNod System's ability to acquire adequate specimens of cellular matter suitable for the cytologic evaluation of targeted lung lesions, under real-time visualization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device/Procedure-Related Safety Events</measure>
    <time_frame>Procedure through Post-procedure call; 6-8 days post-procedure.</time_frame>
    <description>Occurrence and severity of Adverse Events related to the iNod System biopsy procedures, as well as Adverse Events related to any subsequent Radial EBUS-guided salvage procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visualization</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Lesions visualized during iNod Maneuvers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Lesions accessed where iNod Biopsy Needles were deployed in the target lesion during study maneuvers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquisition</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>iNod maneuvers that acquired specimens of cellular matter for cytology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Solitary Pulmonary Nodule</condition>
  <condition>Biopsy, Fine-Needle</condition>
  <arm_group>
    <arm_group_label>iNod System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iNod System</intervention_name>
    <description>The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
    <arm_group_label>iNod System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is age 18 years or older.

          2. Subject is willing and able to comply with study procedures and provide written
             informed consent to participate in study.

          3. Subject with a predominantly solid lung lesion, 1 cm to 7 cm in diameter, which has
             been identified on chest CT (obtained within 6 weeks) with the intention to undergo a
             clinically indicated bronchoscopic evaluation under routine clinical care. If the
             lesion is partially solid (i.e. there is a ground glass component) then the solid
             portion must make up 80% of the lesion.

          4. Subject for whom the decision to pursue biopsy has been made by the treating physician
             and agreed upon by the subject.

        Exclusion Criteria:

          1. Subjects with pure ground glass opacity, a subsolid target lesion, and/or a ground
             glass opacity identified on Chest CT.

          2. Subjects with lesions that include endobronchial involvement, per Chest CT.

          3. Subjects who lack fitness to undergo flexible bronchoscopy and standard of care Radial
             EBUS-guided cytological assessment evaluations, as determined by the investigator.

          4. Subjects with known coagulopathy.

          5. Subjects who are pregnant or nursing mothers.

          6. Subjects who are currently enrolled in another investigational study that would
             directly interfere with the current study, without prior written approval from the
             sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bowman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director, Boston Scientific</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University Medical School</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University of St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <results_first_submitted>September 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2018</results_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-policy.html).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02832284/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02832284/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>iNod System</title>
          <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>23 Patients were analyzed for primary endpoint. 86 Attempts to access target lesions were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>iNod System</title>
          <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
Per, protocol, each of the 23 enrolled subjects underwent evaluations with the iNod System.
For study subjects for whom an adequate specimen, defined as a specimen that has been confirmed as suitable for cytologic evaluation, is not obtained from the iNod System diagnostic procedure but for whom continuation with endobronchial maneuvers are not contraindicated, additional standard of care (SOC) R-EBUS-guided diagnostic sampling maneuvers should be conducted.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Attepmts at target lesions</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Attepmts at target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" lower_limit="48.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Attepmts at target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Attepmts at target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Attepmts at target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acquisition of Adequate Specimens of Targeted Lung Lesions</title>
        <description>The primary endpoint for the iNod Feasibility Study was clinical success, defined as the iNod System's ability to acquire adequate specimens of cellular matter suitable for the cytologic evaluation of targeted lung lesions, under real-time visualization.</description>
        <time_frame>Intraprocedural</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iNod System</title>
            <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
          </group>
        </group_list>
        <measure>
          <title>Acquisition of Adequate Specimens of Targeted Lung Lesions</title>
          <description>The primary endpoint for the iNod Feasibility Study was clinical success, defined as the iNod System's ability to acquire adequate specimens of cellular matter suitable for the cytologic evaluation of targeted lung lesions, under real-time visualization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device/Procedure-Related Safety Events</title>
        <description>Occurrence and severity of Adverse Events related to the iNod System biopsy procedures, as well as Adverse Events related to any subsequent Radial EBUS-guided salvage procedures.</description>
        <time_frame>Procedure through Post-procedure call; 6-8 days post-procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iNod System</title>
            <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
          </group>
        </group_list>
        <measure>
          <title>Device/Procedure-Related Safety Events</title>
          <description>Occurrence and severity of Adverse Events related to the iNod System biopsy procedures, as well as Adverse Events related to any subsequent Radial EBUS-guided salvage procedures.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visualization</title>
        <description>Lesions visualized during iNod Maneuvers</description>
        <time_frame>Intraprocedural</time_frame>
        <population>Lesions visualized per attempt to visualize lesion</population>
        <group_list>
          <group group_id="O1">
            <title>iNod System</title>
            <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
          </group>
        </group_list>
        <measure>
          <title>Visualization</title>
          <description>Lesions visualized during iNod Maneuvers</description>
          <population>Lesions visualized per attempt to visualize lesion</population>
          <units>Lesions visualization attempts</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions visualization attempts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions visualization attempts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access</title>
        <description>Lesions accessed where iNod Biopsy Needles were deployed in the target lesion during study maneuvers</description>
        <time_frame>Intraprocedural</time_frame>
        <population>Lesions accessed per attempt to access lesion</population>
        <group_list>
          <group group_id="O1">
            <title>iNod System</title>
            <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
          </group>
        </group_list>
        <measure>
          <title>Access</title>
          <description>Lesions accessed where iNod Biopsy Needles were deployed in the target lesion during study maneuvers</description>
          <population>Lesions accessed per attempt to access lesion</population>
          <units>Lesions access attempts</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions access attempts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions access attempts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acquisition</title>
        <description>iNod maneuvers that acquired specimens of cellular matter for cytology</description>
        <time_frame>Intraprocedural</time_frame>
        <population>Specimens of cellular matter for cytology per attempt, to acquire cellular matter.</population>
        <group_list>
          <group group_id="O1">
            <title>iNod System</title>
            <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
          </group>
        </group_list>
        <measure>
          <title>Acquisition</title>
          <description>iNod maneuvers that acquired specimens of cellular matter for cytology</description>
          <population>Specimens of cellular matter for cytology per attempt, to acquire cellular matter.</population>
          <units>Specimens of cellular matter for cytolog</units>
          <param>Count of Units</param>
          <units_analyzed>Specimens of cellular matter for cytolog</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Specimens of cellular matter for cytolog</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the Baseline/Consenting Visit, through study exit; typically 7 days.</time_frame>
      <desc>Any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons, whether or not related to the investigational medical device.
NOTE 1: This includes events related to the investigational medical device or comparator.
NOTE 2: This definition includes events related to the procedures involved (any procedure in the clinical investigation plan).</desc>
      <group_list>
        <group group_id="E1">
          <title>iNod System</title>
          <description>Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
iNod System: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pseudomonas Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not powered or designed as a study of diag. yield. Nor was this study designed to follow pts. with indeterminate cytology diagnoses. Non-malig. cytopathology. findings would require 6 mos. of follow-up (min. expect.) for a yield study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>G Mark Grubb, RN, CCRA</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>412 749 1423</phone>
      <email>grubbm@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

